US FDA approves TG Therapeutics’ multiple sclerosis drug EP News Bureau Dec 29, 2022 The approval by the US Food and Drug Administration (USFDA) widens the number of such drugs available for treating the disorder to…
FDA withdraws approval for TG Therapeutics cancer treatment Reuters Jun 3, 2022 The withdrawal has been due to concerns of higher risk of death in patients receiving the drug
Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or… EP News Bureau Feb 9, 2021 Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…
